MTOR and pancreatic neuroendocrine tumor: Regarding molecularly targeted therapies, everolimus (a mammalian target of rapamycin mTOR inhibitor, refs. 128–130), three tyrosine kinase inhibitors with antiangiogenic activity (sunitinib for pancreatic NETs, refs. 131; surufatinib in China, refs. 132, 133 for all NETs; and probably soon cabozantinib, ref. 134), and belzutifan (for patients with von Hippel–Lindau (VHL) disease, targeting HIF-2α, ref. 135) have been approved.